Boothbay Fund Management, LLC Biomarin Pharmaceutical Inc Put Options Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $153,126 - $170,064	1,800 Added 9.0%	21,800 $1.93 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $988,152 - $1.14 Million	11,400 Added 132.56%	20,000 $1.73 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $535,214 - $715,347	6,100 Added 244.0%	8,600 $836,000
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $5.58 Million - $7.5 Million	-69,000 Reduced 96.5%	2,500 $258,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $5.87 Million - $6.93 Million	71,500 New	71,500 $6.06 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $973,068 - $1.21 Million	13,100 Added 64.85%	33,300 $2.57 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $1.45 Million - $1.85 Million	20,200 New	20,200 $1.79 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.